NCT02175121 - Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus | Biotech Hunter

Enrollment

172

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Diabetes Mellitus, Type II

Interventions

DRUG

Placebo

Tablet, once daily for 28 days

DRUG

PF-06291874

Tablet, 15 mg, once daily for 28 days

DRUG

PF-06291874

Tablet, 35 mg, once daily for 28 days

DRUG

PF-06291874

Tablet, 75 mg, once daily for 28 days

DRUG

PF-06291874

Tablet, 150 mg, once daily for 28 days

Trial Locations (19)

14202

Buffalo Clinical Research Center, LLC, Buffalo

27265

High Point Clinical Trials Center, LLC, High Point

32720

Avail Clinical Research, LLC, DeLand

32806

Compass Research, LLC, Orlando

33125

SeaView Research, Inc., Miami

33126

SeaView Research, Inc., Miami

33143

Miami Research Associates, Inc., South Miami

MRA Clinical Research, LLC, South Miami

MRA Clinical Research, South Miami

40213

Louisville Metabolic and Atherosclerosis Research Center, Louisville

45255

Community Research, Cincinnati

55404

DaVita Clinical Research, Minneapolis

78229

Clinical Trials of Texas, Inc., San Antonio

91911

Profil Institute for Clinical Research, Inc., Chula Vista

92801

Anaheim Clinical Trials, LLC, Anaheim

94598

Diablo Clinical Research, Inc., Walnut Creek

98057

Rainier Clinical Research Center, Inc., Renton

07724

Clinilabs, Inc., Eatontown

08053

PRA International, Marlton